169 related articles for article (PubMed ID: 26337803)
1. Radioiodinated PARP1 tracers for glioblastoma imaging.
Salinas B; Irwin CP; Kossatz S; Bolaender A; Chiosis G; Pillarsetty N; Weber WA; Reiner T
EJNMMI Res; 2015 Dec; 5(1):123. PubMed ID: 26337803
[TBL] [Abstract][Full Text] [Related]
2. Non-invasive PET Imaging of PARP1 Expression in Glioblastoma Models.
Carney B; Carlucci G; Salinas B; Di Gialleonardo V; Kossatz S; Vansteene A; Longo VA; Bolaender A; Chiosis G; Keshari KR; Weber WA; Reiner T
Mol Imaging Biol; 2016 Jun; 18(3):386-92. PubMed ID: 26493053
[TBL] [Abstract][Full Text] [Related]
3. Dual-Modality Optical/PET Imaging of PARP1 in Glioblastoma.
Carlucci G; Carney B; Brand C; Kossatz S; Irwin CP; Carlin SD; Keliher EJ; Weber W; Reiner T
Mol Imaging Biol; 2015 Dec; 17(6):848-55. PubMed ID: 25895168
[TBL] [Abstract][Full Text] [Related]
4. PARPi-FL--a fluorescent PARP1 inhibitor for glioblastoma imaging.
Irwin CP; Portorreal Y; Brand C; Zhang Y; Desai P; Salinas B; Weber WA; Reiner T
Neoplasia; 2014 May; 16(5):432-40. PubMed ID: 24970386
[TBL] [Abstract][Full Text] [Related]
5. Fluorine-18 labeled poly (ADP-ribose) polymerase1 inhibitor as a potential alternative to 2-deoxy-2-[
Demétrio de Souza França P; Roberts S; Kossatz S; Guru N; Mason C; Zanoni DK; Abrahão M; Schöder H; Ganly I; Patel SG; Reiner T
Nucl Med Biol; 2020; 84-85():80-87. PubMed ID: 32135475
[TBL] [Abstract][Full Text] [Related]
6. Preclinical and first-in-human-brain-cancer applications of [
Young RJ; Demétrio De Souza França P; Pirovano G; Piotrowski AF; Nicklin PJ; Riedl CC; Schwartz J; Bale TA; Donabedian PL; Kossatz S; Burnazi EM; Roberts S; Lyashchenko SK; Miller AM; Moss NS; Fiasconaro M; Zhang Z; Mauguen A; Reiner T; Dunphy MP
Neurooncol Adv; 2020; 2(1):vdaa119. PubMed ID: 33392502
[TBL] [Abstract][Full Text] [Related]
7. PARP1-targeted fluorescence molecular endoscopy as novel tool for early detection of esophageal dysplasia and adenocarcinoma.
Marcazzan S; Braz Carvalho MJ; Nguyen NT; Strangmann J; Slotta-Huspenina J; Tenditnaya A; Tschurtschenthaler M; Rieder J; Proaño-Vasco A; Ntziachristos V; Steiger K; Gorpas D; Quante M; Kossatz S
J Exp Clin Cancer Res; 2024 Feb; 43(1):53. PubMed ID: 38383387
[TBL] [Abstract][Full Text] [Related]
8. Iodinated benzimidazole PARP radiotracer for evaluating PARP1/2 expression in vitro and in vivo.
Anderson RC; Makvandi M; Xu K; Lieberman BP; Zeng C; Pryma DA; Mach RH
Nucl Med Biol; 2016 Dec; 43(12):752-758. PubMed ID: 27689533
[TBL] [Abstract][Full Text] [Related]
9. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
[TBL] [Abstract][Full Text] [Related]
10. Detection and delineation of oral cancer with a PARP1 targeted optical imaging agent.
Kossatz S; Brand C; Gutiontov S; Liu JT; Lee NY; Gönen M; Weber WA; Reiner T
Sci Rep; 2016 Feb; 6():21371. PubMed ID: 26900125
[TBL] [Abstract][Full Text] [Related]
11. PARP-1-Targeted Radiotherapy in Mouse Models of Glioblastoma.
Jannetti SA; Carlucci G; Carney B; Kossatz S; Shenker L; Carter LM; Salinas B; Brand C; Sadique A; Donabedian PL; Cunanan KM; Gönen M; Ponomarev V; Zeglis BM; Souweidane MM; Lewis JS; Weber WA; Humm JL; Reiner T
J Nucl Med; 2018 Aug; 59(8):1225-1233. PubMed ID: 29572254
[TBL] [Abstract][Full Text] [Related]
12. DNA Repair Enzyme Poly(ADP-Ribose) Polymerase 1/2 (PARP1/2)-Targeted Nuclear Imaging and Radiotherapy.
Nguyen NT; Pacelli A; Nader M; Kossatz S
Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267438
[TBL] [Abstract][Full Text] [Related]
13. Detection and Delineation of Oral Cancer With a PARP1-Targeted Optical Imaging Agent.
Kossatz S; Weber W; Reiner T
Mol Imaging; 2017; 16():1536012117723786. PubMed ID: 28856922
[TBL] [Abstract][Full Text] [Related]
14. PARP1-siRNA suppresses human prostate cancer cell growth and progression.
Lai Y; Kong Z; Zeng T; Xu S; Duan X; Li S; Cai C; Zhao Z; Wu W
Oncol Rep; 2018 Apr; 39(4):1901-1909. PubMed ID: 29393407
[TBL] [Abstract][Full Text] [Related]
15. Discriminating radiation injury from recurrent tumor with [
Donabedian PL; Kossatz S; Engelbach JA; Jannetti SA; Carney B; Young RJ; Weber WA; Garbow JR; Reiner T
EJNMMI Res; 2018 Jul; 8(1):59. PubMed ID: 29974335
[TBL] [Abstract][Full Text] [Related]
16. Nanoemulsion-Based Delivery of Fluorescent PARP Inhibitors in Mouse Models of Small Cell Lung Cancer.
Gonzales J; Kossatz S; Roberts S; Pirovano G; Brand C; Pérez-Medina C; Donabedian P; de la Cruz MJ; Mulder WJM; Reiner T
Bioconjug Chem; 2018 Nov; 29(11):3776-3782. PubMed ID: 30354077
[TBL] [Abstract][Full Text] [Related]
17. A phase I study of a PARP1-targeted topical fluorophore for the detection of oral cancer.
Demétrio de Souza França P; Kossatz S; Brand C; Karassawa Zanoni D; Roberts S; Guru N; Adilbay D; Mauguen A; Valero Mayor C; Weber WA; Schöder H; Ghossein RA; Ganly I; Patel SG; Reiner T
Eur J Nucl Med Mol Imaging; 2021 Oct; 48(11):3618-3630. PubMed ID: 33954826
[TBL] [Abstract][Full Text] [Related]
18. PARP targeted Auger emitter therapy with [
Ambur Sankaranarayanan R; Florea A; Allekotte S; Vogg ATJ; Maurer J; Schäfer L; Bolm C; Terhorst S; Classen A; Bauwens M; Morgenroth A; Mottaghy FM
EJNMMI Res; 2022 Sep; 12(1):60. PubMed ID: 36104637
[TBL] [Abstract][Full Text] [Related]
19. Urokinase-Type Plasminogen Activator Receptor as a Potential PET Biomarker in Glioblastoma.
Persson M; Nedergaard MK; Brandt-Larsen M; Skovgaard D; Jørgensen JT; Michaelsen SR; Madsen J; Lassen U; Poulsen HS; Kjaer A
J Nucl Med; 2016 Feb; 57(2):272-8. PubMed ID: 26429955
[TBL] [Abstract][Full Text] [Related]
20. Correlation between molar activity, injection mass and uptake of the PARP targeting radiotracer [
Chan CY; Hopkins SL; Guibbal F; Pacelli A; Baguña Torres J; Mosley M; Lau D; Isenegger P; Chen Z; Wilson TC; Dias G; Hueting R; Gouverneur V; Cornelissen B
EJNMMI Res; 2022 Oct; 12(1):67. PubMed ID: 36210377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
